Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Texas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Texas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Texas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Ebrahim Delpassand (NPI 1912923467)

Field	Value
Entity Type	Individual
Organization	Ebrahim Delpassand
Address	9701 Richmond Ave
City	Houston
State	TX
ZIP	77042
Taxonomy	Nuclear Radiology Physician
NPI Enumerated	July 15, 2006

Payer Source	Total Paid
Medicare	$4.4M
Medicaid	$0

Key Findings

This provider’s Medicare revenue is overwhelmingly driven by radiopharmaceutical therapy: A9607 (Lutetium lu 177 vipivotide tetraxetan, therapeutic, 1 millicurie) accounts for $4.4M in Medicare payments and 99.4% of the provider’s total Medicare revenue, indicating the practice is functionally organized around delivery of Lu-177 therapeutic doses rather than general imaging or broad outpatient care. The granular code mix (A9607 plus other radiopharmaceutical-related codes) is consistent with a specialty nuclear radiology therapeutic service line.

Revenue concentration is extreme: the precomputed top 3 Medicare codes account for 99.9% of total Medicare revenue, concentrating financial performance almost entirely in a tiny set of therapy-related CPT/HCPCS items. This degree of dependence on a single drug/procedure line heightens operational and reimbursement risk if utilization, policy, or pricing for those codes changes.

The provider is effectively a Medicare-only biller: lifetime Medicare revenue is $4.4M while there is no Medicaid billing on file. This single-payer reliance means comparisons, competitive positioning, and any growth strategy should be evaluated primarily in the Medicare market rather than across a mixed payer book.

Competitive standing on the top therapy code is notable: for A9607 the provider ranks #4 of 44 nationally and sits in the 93th percentile by volume for that code, although the dataset characterizes the volume for this code as "typical, unremarkable." In plain terms, the practice is among the higher-volume billers of A9607 nationally but that standing is not labeled as an outlier by the data.

For complementary radiopharmaceutical procedure coding, 79101 appears at materially elevated relative volume: 122 claims produced $14.3K in revenue (0.3% of total Medicare revenue) and this provider ranks #8 of 302 nationally (98th percentile), a descriptor the data labels as "notably above typical national volume." This suggests the practice is also an active administrator of radiopharmaceutical injections beyond the Lu-177 product itself, even though those procedures contribute only a small share of dollars.

Evaluation-and-management activity is minimal relative to therapeutic billing: 99215 generated $9.4K (0.2% of Medicare revenue) across 65 claims (rank #46190 of 145531, 68th percentile) and 99205 contributed $4.5K (0.1%) across 25 claims (rank #32786 of 66257, 48th percentile). Together these figures show the provider bills some E/M visits but that office/outpatient evaluation work represents a very small adjunct to the dominant therapeutic service line.

Anomalous ancillary coding is visible: J1940 (Injection, furosemide, up to 20 mg) shows 82 claims with an average paid/claim of $0 and $0 revenue recorded, while still ranking #68 of 363 providers (81th percentile) for claim count. This indicates the provider submitted ancillary medication injection claims that did not generate Medicare payments in the dataset, which may reflect bundling, zero-dollar adjustments, or reporting of services without separate payment.

The provider has long tenure in the NPI registry (enumerated 2006-07-15, approximately 20 years), signaling an established practice footprint; combined with the concentrated revenue mix, this suggests a long-standing specialty operation focused on therapeutic nuclear medicine rather than a recently pivoted or mixed-service practice.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

5 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
A9607	Lutetium lu 177 vipivotide tetraxetan, therapeutic, 1 millicurie	21,410	$210	$4.4M
79101	In this procedure, the provider injects a radiopharmaceutical substance into the venous blood stream to treat the patient’s condition.	120	$120	$14.3K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	70	$150	$9.4K
99205	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the provider…	30	$180	$4.5K
J1940	Injection, furosemide, up to 20 mg	80	$0	$0

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 5 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Texas Distribution

Ebrahim Delpassand — 2 of 4 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Texas

Full comparison — all codes billed, vs. state median

5 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
A9607	1	10	15,800	$200	$2.6M
99215	2,842	8,730	40	$120	$9.2K
99205	2,121	4,320	30	$150	$5.5K
79101	2	20	30	$80	$3.6K
J1940	4	20	20	$1	$30

Nearby Providers

Other providers in the same ZIP code as Ebrahim Delpassand, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Wilcare, Inc.	TX	Personal Care Attendant	$0	$54M
Everose Healthcare, Inc.	TX	Personal Care Attendant	$0	$52.8M
Maxim Healthcare Services, Inc.	TX	Home Health Agency	$0	$16.8M
U. S. Anesthesia Partners Of Texas, P.A.,	TX	Anesthesiology Physician	$0	$16.7M
United America Home Health Services, Inc	TX	Home Health Agency	$0	$12.5M
New Essence Health Care Inc.	TX	Home Health Agency	$0	$12.3M
Christian Provider Services Inc	TX	Personal Care Attendant	$0	$11.8M
Diversified Health Solutions LLC	TX	Home Health Agency	$0	$11.2M
Auspicious Laboratory Inc.	TX	Clinical Medical Laboratory	$788.9K	$1.9M
Kimberly Dodd	TX	Family Nurse Practitioner	$2.1M	$0

Ebrahim Delpassand — Billing Profile & Reimbursement Data

Sign up for Ebrahim Delpassand — Billing Profile & Reimbursement Data policy alerts

Ebrahim Delpassand — Billing Profile & Reimbursement Data

Sign up for Ebrahim Delpassand — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Nearby Providers

Frequently Asked Questions

References